In our previous study, leucine-rich alpha-2 glycoprotein (LRG) was identified as an inflammatory biomarker through the semiquantitative proteomic analysis of sera in patients with rheumatoid arthritis before and after anti-tumor necrosis factor (TNF) therapy [18]. The gene discussed is TNF; the disease is rheumatoid arthritis.